Production of Carrier Free Actinium-225/ Bismuth-213 and the Application Possibilities for Alpha-Immunotherapy

摘要

For the selective irradiation of cancer cells, alpha-immunotherapy uses oc-emitters such as Bi-213 and Ac-225 that are linked to monoclonal antibodies or peptides through bifunctional chelators. Two production routes were presented in the paper. One, via Th-229, has been further investigated, modified and improved, e.g. the separation processes, generator loading techniques and elution strategies. The alternative production route is to produce Ac-225 by proton irradiation of Ra-226 in a cyclotron through the reaction Ra-226(p,2n)Ac-225. The feasibility of this method was approved. The generator product, carrier free Bi-213, is labelled to various monoclonal antibodies. For testing and application of alpha-immunotherapy, the regular supply of alpha-nuclides to hospitals that have embarked in pre-clinical and clinical trials is prerequisite. Furthermore the paper will give an overview on the different application possibilities of the ITU-produced Bi-213 in clinical trials. Actinium-225 / Bismuth-213 / Thorium-229 / Radium-226 / Targeted alpha therapy / Cancer / Radionuclide Generator / Radioisotope production / Cyclotron